Gail H. Gasior

Beckman Coulter Foundation — United States

Medicine · Health Sciences

10h-index2.4kcitations15works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Diagnosis and Treatment(10), Prostate Cancer Treatment and Research(10), Urologic and reproductive health conditions(5), Cytomegalovirus and herpesvirus research(4), Immune Cell Function and Interaction(4)

Publications15 total

Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index
American Journal of Hematology·2011· 222 cited
Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study
Blood·2010· 111 citedOpen Access
Immune monitoring with iTAg™ MHC tetramers for prediction of recurrent or persistent cytomegalovirus (CMV) infection in allogeneic stem cell transplant (SCT) recipients: A prospective multicenter clinical trial
Biology of Blood and Marrow Transplantation·2006· 4 citedOpen Access
Immune Monitoring with iTAg™ MHC Tetramers*: Potential Clinical Utility in the Prediction of Recurrent CMV Reactivation in Allogeneic Stem Cell Transplant Recipients
Journal of Immunotherapy·2004
Reconstitution of CMV-specific CD8+ T-cells following allogeneic stem cell transplantation (SCT): Evaluation of tetramers for prediction of recurrent CMV reactivation
Human Immunology·2004
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
Urology·2000· 335 cited
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial
Urology·2000· 50 cited
PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL
The Journal of Urology·1999· 93 cited
PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL
The Journal of Urology·1999· 5 cited
Analytical and Clinical Performance Characteristics of Hybritech’s Tandem-R free PSA Assay during a Large Multicenter Clinical Trial to Determine the Clinical Utility of Percentage of Free Prostate-specific Antigen
Clinical Chemistry·1999· 7 citedOpen Access
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
The Journal of Urology·1999· 99 cited
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
JAMA·1998· 1.2k cited
Analytical performance of the Tandem®-R free PSA immunoassay measuring free prostate-specific antigen
Clinical Chemistry·1997· 29 citedOpen Access
Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen.
PubMed·1997· 32 cited
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total psa, prostate volume, and age
Urology·1996· 255 citedOpen Access

Frequent Co-authors

Paula C. Southwick(15), Kathleen G Loveland(9), Kevin M. Slawin(6), Robert C. Flanigan(6), Patrick C. Walsh(6), Alan W. Partin(5), Michael K. Brawer(5), Jerome P. Richie(5), Peter T. Scardino(5), Paul H. Lange(5), Robert E. Parson(5), William J. Catàlona(5), Kurtis R. Bray(5), Linda A. Sullivan(5), Anup Patel(4), Jan J. Cornelissen(4), Rik A. Brooimans(4), Christopher Boyce(4), Jean B. deKernion(3), Eric N.P. Subong(3)